Increased serum neopterin levels in women with polycystic ovary syndrome

Annals of Clinical and Laboratory Science

Volumn 36, Issue 3, 2006, Pages 267-272

  Barutcuoglu, Burcu ^a   Bozdemir, A Erkin ^a   Dereli, Didem ^a   Parildar, Zuhal ^a   Mutaf, M Isil ^a   Ozmen, Dilek ^a   Bayindir, Oya ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

C reactive protein; Cardiovascular disease; Neopterin; Polycystic ovary syndrome; WBC count

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEOPTERIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY RISK; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIPOPROTEIN BLOOD LEVEL; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; LEUKOCYTE COUNT; NEOPTERIN; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 33748367879     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Stein IF, Leventhal MI. Amenorrhea associated with polycystic ovaries. Am J Obtet Gynecol 1935;29:181-191.
2. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80:123-127.
3. Wild RA, Grubb BG, Hartz A, VanNort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990; 54:255-259.
4. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
5. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-1415.
6. Conway GS, Agrawal R, Batteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37:119-126.
7. Kelly HL, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:2453-2455.
8. Frishman WH. Biologic markers as predictors of cardiovascular disease. Am J Med 1998;104:18S-27S.
9. Garcia-Moll X, Cole D, Zouridakis E, Kaski JC, Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000;83:346-350.
10. Huber C, Batchelor JR, Fuchs D, Lang A, Niederwieser D, Raibnegger G, Swetly P, Troppamir J, Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-316.
11. Gupta S, Fredericks S, Schwartzman RA, Holt DW, Kaski JC. Serum neopterin in acute coronary syndromes. Lancet 1997;349:1252-1253.
12. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Col Cardiol 2000;35:956-962.
13. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. Br Med J 2000;321: 199-204.
14. Boulman N, Levy Y, Lebia R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-2165.
15. Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis 2004;172:1-6.
16. Chang RJ. Polycystic ovary syndrome: diagnostic criteria. In: Polycystic Ovary Syndrome, 1st ed (RJ Chang, JJ Heindel, A Dunaif, Eds), Marcel Dekker, New York, 2002; pp 361-366.
17. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21:1440-1447.
18. Turgan N, Habif S, Parildar Z, Ozmen D, Mutaf I, Erdener D, Bayindir O. Association between homocysteine and neopterin in healthy subjects measured by a simple HPLC-fluorometric method. Clin Biochem 2001;34:271-275.
19. Ovalle F, Aziz R. Insulin resistance, polycystic ovary syndrome and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-1105.
20. Sam S, Legro RS, Bertley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisiters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4797-4802.
21. Margolin E, Zhornitzki T, Kopernik G, Kogan S, Schattner A, Knobler H. Polycystic ovary syndrome in postmenopausal women-markers of the metabolic syndrome. Maturitas 2005;50:331-336.
22. Van Lente F. Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 2000;293:31-52.
23. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003 21;92:17K-22K.
24. Ridker PM, Hennekens CH, Buring JH, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEJM 2000;342:836-843.
25. Taponen S, Martikainen H, Jarvelin M-J, Sovio U, Laitinen J, Pouta A, Martikainen A-L, McCarthy MI, Franks S, Paldanius M, Ruokonen A. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab 2004;89:2114-2118.
26. Ridker PM, Hennekens CH, Buring JH, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. NEJM 2000;342:836-843.
27. Gown AM, Tsukada T, Ross R. Human atherosclerosis, II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986;125:191-207.
28. Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995;91:2844-2850.
29. Schobersberger W, Hoffmann G, Grote J, Wachter H, Fuchs D. Induction of inducible nitric oxide syntase expression by neopterin in vascular smooth muscle cells. FEBS Lett 1995;377:461-464.
30. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res 1999;19:1721-1728.
31. Brown DW, Giles WH, Croft JB. White blood cell count: An independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54;316-322.
32. Avanzas P, Arroyo-Espliguero R, Cosin-Sales L, Aldama G, Pizzi C, Quiles J, Kaski JC. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 2004;90:847-852.
33. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, Lombardi G. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2-5.